Business
1st Human Use of Cardiac Cann
1st Human Use of Cardiac Cann.
About this update from Rua Life Sciences Plc
[{"type":"text","content":"\n RNS Number : 6603Z Aortech International PLC 23 July 2008 \n \n\n\n\n\n\n\nFor Immediate Release\n\n\nJuly 23, 2008\n\n\n\n\n\nAorTech International plc \n('AorTech' or the 'Company')\n\n1st Human Use of Cardiac Cannulae Products by Avalon Laboratories, LLC. \n\nAorTech International plc (AIM:AOR), the biomaterials and medical device development company, announces success with early stage clinical use of its proprietary biostable co-polymer Elast-Eon™ in pulmonary support cannulae, designed and manufactured by Avalon Laboratories, LLC. ('Avalon'). The first human use of these products has occurred in the UK. Preparations are being made for US launch subsequent to US FDA approval. This first clinical use follows the exclusive licence granted to Avalon for the use of Elast-Eon™ in cardiac and pulmonary cannulae products in December 2006.\n\nThe first of several anticipated Avalon applications of Elast-Eon materials is with the Avalon Elite Cannulae. These devices are intended to help provide life saving lung support for patients suffering from acute lung failure. These cannulae drain oxygen-depleted blood and infuse oxygen rich blood directly into the patient's heart. Since lungs receive blood that has already been oxygenated, they are allowed to rest. Resting the lungs has been shown to be extremely beneficial for recovery from acute lung failure. \n\nAvalon plans to incorporate the Elast-Eon material into other new and existing products in the future.\n\nPrivately held Avalon is the world's leading supplier of cardiopulmonary vascular cannulae, which are critical disposable components that connect patients to heart and lung machines and other circulatory support devices. Avalon manufactures more than three-quarters of all cannulae used globally and, in 2007, produced more than 1.8 million cannulae on a contract basis to the world's leading healthcare suppliers.\nIn qualification programs with other companies, Elast-Eon is being assessed for a range of additional applications including morbid obesity, neurostimulation, diabetes, women's health and cardiovascular devices.\n\nFrank Maguire, CEO of AorTech said: \n\n'Over...